Authors: Ishaq, S Green, JRB

Citation: S. Ishaq et Jrb. Green, Tolerability of aminosalicylates in inflammatory bowel disease, BIODRUGS, 15(5), 2001, pp. 339-349

Authors: Green, JRB Lobo, AJ Giaffer, M Travis, S Watkins, HC

Citation: Jrb. Green et al., Maintenance of Crohn's disease over 12 months: fixed versus flexible dosing regimen using budesonide controlled ileal release capsules, ALIM PHARM, 15(9), 2001, pp. 1331-1341

Authors: Pearce, CB Duncan, HD Timmis, L Green, JRB

Citation: Cb. Pearce et al., Assessment of the prevalence of infection with Helicobacter pylori in patients with inflammatory bowel disease, EUR J GASTR, 12(4), 2000, pp. 439-443

Authors: Kumar, BN Smith, MSH Walsh, RM Green, JRB

Citation: Bn. Kumar et al., Sensorineural hearing loss in ulcerative colitis, CLIN OTOLAR, 25(2), 2000, pp. 143-145

Authors: Green, JRB

Citation: Jrb. Green, Balsalazide and azathioprine or 6-mercaptopurine, GASTROENTY, 117(6), 1999, pp. 1513-1514

Authors: Green, JRB Gibson, JA Kerr, GD Swarbrick, ET Lobo, AJ Holdsworth, CD Crowe, JP Schofield, KJ Taylor, MD

Citation: Jrb. Green et al., Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months, ALIM PHARM, 12(12), 1998, pp. 1207-1216